These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31456453)

  • 1. Cost of ADHD treatment using methylphenidate and atomoxetine in the South African private healthcare sector.
    Munasur-Naidoo AP; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):677-684. PubMed ID: 31456453
    [No Abstract]   [Full Text] [Related]  

  • 2. Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study.
    Munasur-Naidoo AP; Truter I
    Int J Clin Pharm; 2019 Aug; 41(4):859-863. PubMed ID: 31313002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
    Štuhec M; Locatelli I; Švab V
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADHD Medication Trends in Turkey: 2009-2013.
    Öner Ö; Yilmaz EŞ; Karadağ H; Vural M; Vural EH; Akbulat A; Gürsöz H; Türkçapar H; Kerman S
    J Atten Disord; 2017 Dec; 21(14):1192-1197. PubMed ID: 24554298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J; Dilla T; Arellano J
    BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.
    Treceño C; Martín Arias LH; Sáinz M; Salado I; García Ortega P; Velasco V; Jimeno N; Escudero A; Velasco A; Carvajal A
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):435-41. PubMed ID: 22253017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on drugs for hyperactivity in childhood.
    Drug Ther Bull; 2007 May; 45(5):37-40. PubMed ID: 17536494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine.
    Schulz KP; Bédard AV; Fan J; Hildebrandt TB; Stein MA; Ivanov I; Halperin JM; Newcorn JH
    J Am Acad Child Adolesc Psychiatry; 2017 Jul; 56(7):602-609.e2. PubMed ID: 28647012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD.
    Snircova E; Marcincakova-Husarova V; Hrtanek I; Kulhan T; Ondrejka I; Nosalova G
    Pediatr Int; 2016 Jun; 58(6):476-81. PubMed ID: 26579704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD.
    Ni HC; Lin YJ; Gau SS; Huang HC; Yang LK
    J Atten Disord; 2017 Jan; 21(1):27-39. PubMed ID: 23475825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
    Warrer P; Thomsen PH; Dalsgaard S; Hansen EH; Aagaard L; Wallach Kildemoes H; Rasmussen HB
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):354-61. PubMed ID: 26891424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.